These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 28699217)

  • 41. De-escalation of biological therapy in inflammatory bowel disease: Benefits and risks.
    Fredericks E; Watermeyer G
    S Afr Med J; 2019 Sep; 109(10):745-749. PubMed ID: 31635571
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Role of Early Biologic Therapy in Inflammatory Bowel Disease.
    Berg DR; Colombel JF; Ungaro R
    Inflamm Bowel Dis; 2019 Nov; 25(12):1896-1905. PubMed ID: 30934053
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Risk of postoperative infection in patients with inflammatory bowel disease].
    Ahn HS; Lee SK; Kim HJ; Jang JY; Joo KR; Dong SH; Kim BH; Lee JI; Chang YW; Chang R
    Korean J Gastroenterol; 2006 Nov; 48(5):306-12. PubMed ID: 17132918
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Medical Therapy for Inflammatory Bowel Disease.
    Grevenitis P; Thomas A; Lodhia N
    Surg Clin North Am; 2015 Dec; 95(6):1159-82, vi. PubMed ID: 26596920
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety profile of IBD therapeutics: infectious risks.
    Afif W; Loftus EV
    Gastroenterol Clin North Am; 2009 Dec; 38(4):691-709. PubMed ID: 19913209
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Pharmacotherapy of inflammatory bowel disease].
    Jojić N
    Acta Chir Iugosl; 2000; 47(1-2):51-5. PubMed ID: 10953366
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Croatian consensus on the treatment of inflammatory bowel diseases with biologic therapy].
    Vucelić B; Cuković-Cavka S; Banić M; Bilić A; Borzan V; Duvnjak M; Katicić M; Kolacek S; Krznarić Z; Kujundzić M; Marusić M; Mihaljević S; Mijandrusić BS; Persić M; Simunić M; Skurla B; Stimac D; Tonkić A; Troskot B
    Acta Med Croatica; 2013 Apr; 67(2):75-87. PubMed ID: 24471291
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Complications of biologics in inflammatory bowel disease.
    Sousa P; Allez M
    Curr Opin Gastroenterol; 2015 Jul; 31(4):296-302. PubMed ID: 26039721
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Infections and biologic therapy in rheumatoid arthritis: our changing understanding of risk and prevention.
    Winthrop KL
    Rheum Dis Clin North Am; 2012 Nov; 38(4):727-45. PubMed ID: 23137579
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risks and benefits of biologic therapy for IBD.
    Hommes DW
    J Pediatr Gastroenterol Nutr; 2009 Apr; 48 Suppl 2():S52-3. PubMed ID: 19300125
    [No Abstract]   [Full Text] [Related]  

  • 51. [Infections in inflammatory bowel disease].
    Zeissig S; Schmelz R
    Dtsch Med Wochenschr; 2016 Feb; 141(3):196-200. PubMed ID: 26841183
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System.
    Deepak P; Stobaugh DJ; Ehrenpreis ED
    J Gastrointestin Liver Dis; 2013 Sep; 22(3):269-76. PubMed ID: 24078983
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systematic review with meta-analysis: biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease.
    Piovani D; Danese S; Peyrin-Biroulet L; Nikolopoulos GK; Bonovas S
    Aliment Pharmacol Ther; 2020 May; 51(9):820-830. PubMed ID: 32170782
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The risks and benefits of early immunosuppression and biological therapy.
    Sands BE
    Dig Dis; 2012; 30 Suppl 3():100-6. PubMed ID: 23295699
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of biological molecules in the treatment of inflammatory bowel disease.
    Nielsen OH; Seidelin JB; Munck LK; Rogler G
    J Intern Med; 2011 Jul; 270(1):15-28. PubMed ID: 21241384
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.
    Lawrance IC; Radford-Smith GL; Bampton PA; Andrews JM; Tan PK; Croft A; Gearry RB; Florin TH
    J Gastroenterol Hepatol; 2010 Nov; 25(11):1732-8. PubMed ID: 21039834
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The European (ECCO) Consensus on infection in IBD: what does it change for the clinician?
    Rahier JF; Yazdanpanah Y; Colombel JF; Travis S
    Gut; 2009 Oct; 58(10):1313-5. PubMed ID: 19749130
    [No Abstract]   [Full Text] [Related]  

  • 58. A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease.
    Naganuma M; Kunisaki R; Yoshimura N; Takeuchi Y; Watanabe M
    J Gastroenterol; 2013 May; 48(5):595-600. PubMed ID: 23053426
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapy of inflammatory bowel disease.
    Sands BE
    Gastroenterology; 2000 Feb; 118(2 Suppl 1):S68-82. PubMed ID: 10868899
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Infection-related hospitalizations in the first year after inflammatory bowel disease diagnosis.
    Ko MK; Ng SC; Mak LY; Li MK; Lo FH; Ng CK; Lao WC; Tsang S; Chan KH; Hui YT; Shan EH; Loo CK; Hui AJ; To WP; Hung IF; Leung WK
    J Dig Dis; 2016 Sep; 17(9):610-617. PubMed ID: 27533786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.